Female Urethral Stricture
Female urethral stricture (FUS) is a pathological narrowing of the female urethra resulting from scar tissue formation — a condition that is far less common than its male counterpart, significantly underdiagnosed, and frequently mismanaged with repeated dilations before definitive reconstruction is considered. Bladder outlet obstruction (BOO) accounts for only 2.7–8% of women referred for voiding dysfunction, and true anatomical urethral stricture represents 4–20% of those cases — yet among women with refractory lower urinary tract symptoms, FUS is a frequently overlooked diagnosis.[1][2]
For procedural selection and the full range of repairs, see the Urethral Reconstruction treatment atlas and its female urethroplasty techniques.
Epidemiology
FUS is considered rare but is substantially underdiagnosed due to non-specific presentation, lack of a standardized diagnostic definition, and historical tendency to attribute obstructive voiding symptoms in women to functional rather than anatomical causes.[3] There is no high-quality population prevalence data. An estimated 10% of women presenting with obstructive voiding symptoms will have a true anatomical urethral stricture on objective evaluation.[4]
The evidence base remains dominated by small surgical series with inconsistent definitions and follow-up; reported patency is not a uniform measure of symptom relief or cure.[2][3]
Etiology
| Category | Key Causes |
|---|---|
| Iatrogenic | Traumatic or repeated urethral catheterization (most common); urethral dilation itself causing fibrosis; pelvic surgery; radiation therapy; prior anti-incontinence procedures |
| Lichen sclerosus (LS) | Progressive inflammatory fibrosis; typically distal/meatal; recurs in genital tissue; requires oral mucosa for repair |
| Inflammatory | Recurrent UTIs; urethritis; sexually transmitted infections |
| Traumatic | Blunt pelvic trauma; obstetric injury (cephalopelvic disproportion, instrumented delivery) |
| Idiopathic | No identifiable cause; diagnosis of exclusion |
| Other | Malignancy; radiation; urethral or vaginal atrophy; lichen planus |
Catheterization as a Cause. Iatrogenic injury from urethral catheterization is the single most common identifiable etiology. This includes both single traumatic catheterizations and — critically — repeated urethral dilations performed to treat stricture, which themselves cause progressive spongiofibrotic injury and worsen the underlying disease. Urethral dilation has been described as "often overused and unnecessary, leading to significant healthcare costs" in the management of FUS.[2]
Diagnostic Criteria and Workup
Diagnosis is challenging due to non-specific symptoms and the absence of a universally accepted diagnostic definition. A structured workup is essential.
Clinical Presentation
Women with FUS most commonly present with obstructive voiding symptoms:[4][3]
- Weak or reduced urinary stream
- Urinary hesitancy and straining to void
- Incomplete bladder emptying
- Post-void dribbling
- Urinary frequency, urgency, nocturia (secondary to elevated post-void residual)
- Recurrent urinary tract infections
- Urinary retention (acute or chronic)
- Dysuria, urethral pain
Diagnostic Challenge. In contrast to men, obstructive voiding symptoms in women are frequently attributed to overactive bladder or functional voiding dysfunction. FUS should be considered in any woman with persistent obstructive voiding symptoms refractory to behavioral and pharmacological management, prior to labeling the condition as idiopathic or functional.
Diagnostic Modalities
| Test | Findings in FUS | Notes |
|---|---|---|
| Uroflowmetry | Plateau-shaped (flat-top) curve; reduced Qmax | Same pattern as in men; highly suggestive when combined with symptoms |
| Post-void residual (PVR) | Elevated | Confirms incomplete emptying |
| Urethral calibration | Difficulty passing a small catheter raises suspicion | Distinguish fixed scar from pain, guarding, functional obstruction or difficult access; do not force calibration |
| Cystourethroscopy | Direct visualization of narrowing, epithelial pallor, scarring | Gold standard for visualization; does not reliably assess stricture length |
| Voiding Cystourethrography (VCUG) | Classic "wine glass" appearance — prestenotic urethral dilation tapering to narrowing | Defines location and length; essential for surgical planning |
| Video-urodynamics | Combines pressure-flow study with real-time fluoroscopy | Best for complex cases, especially when neurogenic or functional component suspected |
| Pelvic MRI | Evaluates periurethral fibrosis, urethral diverticulum, pelvic anatomy | Indicated for complex anatomy, recurrent strictures, suspected diverticulum |
| Urodynamics | Rules out detrusor underactivity, neurogenic bladder | Indicated when symptoms exceed anatomical findings or treatment response is unexpected |
Interpret fluoroscopy with the rest of the study. Proximal urethral ballooning can occur above a fixed stricture, but a spinning-top appearance is not specific and may reflect dysfunctional voiding. Confirm anatomical scar with examination/endoscopy and use pressure-flow findings and EMG when functional obstruction is possible.[6][7]
Classification
FUS is classified by anatomical location and stricture length:
By Location
| Location | Characteristics |
|---|---|
| Distal / Meatal | Visible at introitus; most commonly LS-related; amenable to meatoplasty or short flap procedures |
| Mid-urethral | Most common location; typically iatrogenic or idiopathic |
| Proximal (near bladder neck) | Least common; most complex; associated with pelvic surgery or radiation |
| Multifocal / Panurethral | Multiple levels; typically LS-related or after radiation |
By Length
- Very short (<0.5 cm): Meatoplasty may suffice
- Short (<2 cm): Flap procedures appropriate
- Long (≥2 cm): Graft urethroplasty required; complex cases may need staged repair
Treatment
Treatment Options
Confirm a fixed anatomical stricture before intervention. Discuss the durability and burden of dilation, intermittent self-dilation and urethroplasty. The AUA supports offering urethroplasty because endoscopic durability is limited. EAU guidance permits initial dilation and repeat dilation with self-dilation for a first recurrence; reconstruction is recommended for further recurrence when a woman cannot self-dilate or wants definitive treatment.[6][8]
Observation
Asymptomatic, incidentally discovered urethral narrowing without obstructive symptoms or elevated PVR may be observed. Active surveillance with uroflowmetry and PVR is appropriate.
Urethral Dilation and DVIU
Urethral dilation remains the most commonly performed first-line treatment despite limited long-term efficacy.[4]
- Composite success rate: ~47%
- Without prior dilations: 58%
- After prior dilations: 27%
- Success decreases substantially with each subsequent dilation
- Repeat dilation risks progressive urethral fibrosis and worsening stricture
After recurrence. Repeated dilation alone has poor durability. Planned dilation or self-dilation may maintain patency but should be described as ongoing management, not cure. Offer reconstructive counseling rather than an indefinite series of procedures. Female DVIU has much less specific evidence than dilation and is not an interchangeable default.[6][8]
Drug-Coated Balloon (Optilume DCB)
Female use remains off-label in the United States: the FDA urethral DCB indication is for adult men, and there is no female “bulbar-equivalent” indication.[9] A 2025 single-center report treated 14 patients and analyzed 12 after exclusions; 11/12 avoided recurrence or repeat intervention at a mean 12 months. No new incontinence was observed. This small uncontrolled series cannot establish long-term safety, comparative efficacy or guaranteed sphincter preservation.[5] DCB should not occupy a routine mandatory step before urethroplasty.
Urethroplasty
Urethroplasty offers a durable reconstructive option for FUS. Discuss it early for recurrent or complex disease and for patients who prefer definitive repair over ongoing dilation. Counseling must include recurrence, fistula, altered stream, donor-site morbidity and new or unmasked urinary incontinence.[1][2][8]
Choosing a Reconstruction
Technique selection depends on stricture location and extent, the quality of the urethra and surrounding tissues, previous surgery and surgeon experience. Neither dorsal nor ventral onlay is universally superior. Oral mucosa and healthy vaginal flaps are established options; diseased or scarred donor tissue needs a different plan.[3][6][8]
A short isolated meatal stenosis may be treated with meatoplasty. Longer disease generally needs augmentation with a flap or graft. Lichen sclerosus, atrophy, radiation, prior fistula and future continence surgery materially affect tissue selection; avoid a rigid length-only algorithm.[1][4]
For graft placement, Martius interposition, catheter duration and operative details, use the female urethroplasty techniques. A clinical decision page cannot specify one catheter schedule for every repair.
Outcomes and Follow-Up
Interpret reported patency with its definition, denominator and follow-up. A urethra kept open by repeated instrumentation is different from a repair that remains open without further treatment. Uncontrolled series do not establish superiority of oral versus vaginal tissue or dorsal versus ventral placement.[2][3]
Track symptoms, uroflow and PVR, and investigate recurrent obstruction or new incontinence. Surveillance should reflect the operation, prior recurrence and tissue disease. Discuss anatomical patency and patient-reported urinary and sexual outcomes separately.
Standardization gap. Turchi and colleagues’ 2025 review of 22 studies describes variable outcome definitions that limit comparisons and supports more consistent patient-reported follow-up.[2]
Videos
See Also
- Urethral Reconstruction treatment atlas
- Female Urethroplasty
- Female Dorsal Onlay Urethroplasty
- Female DVIU & Dilation
References
1. Chakraborty JN, Enganti B, Nayak P. "Female Urethroplasty: A Critical Review of Indications, Techniques and Concerns." Int Urogynecol J. 2025. [PMID: 41204975]. doi:10.1007/s00192-025-06415-4
2. Turchi B, Lumen N, Verla W, Waterloos M. "Female urethral stricture disease: a narrative review on diagnosis, surgical techniques and outcomes." Int J Impot Res. 2025. [PMID: 40348941]. doi:10.1038/s41443-025-01079-6
3. West C, Lawrence A. "Female urethroplasty: contemporary thinking." World J Urol. 2019;37(4):619–629. [PMID: 30456711]. doi:10.1007/s00345-018-2564-4
4. Waterloos M, Verla W. "Female Urethroplasty: A Practical Guide Emphasizing Diagnosis and Surgical Treatment of Female Urethral Stricture Disease." Biomed Res Int. 2019;2019:6715257. [PMID: 30906779]. doi:10.1155/2019/6715257
5. Jelisejevas LA, Tulchiner G, Kink P, Rehder P. "Does Optilume drug-coated balloon dilation compromise female sphincter function?" Int Urol Nephrol. 2025. [PMID: 40244519]. doi:10.1007/s11255-025-04513-2
6. European Association of Urology. EAU Guidelines on Urethral Strictures: Disease Management in Females. 2026. Guideline.
7. European Association of Urology. EAU Guidelines on Non-neurogenic Female LUTS: Disease Management. 2026. Functional and anatomical bladder outlet obstruction. Guideline.
8. Wessells H, Morey A, Souter L, Rahimi L, Vanni A. "Urethral Stricture Disease Guideline Amendment (2023)." J Urol. 2023;210(1):64–71. doi:10.1097/JU.0000000000003482.
9. US Food and Drug Administration. Optilume Urethral Drug Coated Balloon: PMA P210020. Approved indication and labeling. FDA record.